CN101664533A - Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method - Google Patents
Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method Download PDFInfo
- Publication number
- CN101664533A CN101664533A CN 200810051138 CN200810051138A CN101664533A CN 101664533 A CN101664533 A CN 101664533A CN 200810051138 CN200810051138 CN 200810051138 CN 200810051138 A CN200810051138 A CN 200810051138A CN 101664533 A CN101664533 A CN 101664533A
- Authority
- CN
- China
- Prior art keywords
- parts
- portions
- radix
- chronic
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 206010020718 Hyperplasia Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000001154 acute Effects 0.000 title claims abstract description 12
- 230000001684 chronic Effects 0.000 title claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 238000005453 pelletization Methods 0.000 claims abstract description 4
- 229920002472 Starch Polymers 0.000 claims abstract description 3
- 239000000314 lubricant Substances 0.000 claims abstract description 3
- 239000008107 starch Substances 0.000 claims abstract description 3
- 235000019698 starch Nutrition 0.000 claims abstract description 3
- 229940079593 drugs Drugs 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 8
- 241000407170 Curcuma Species 0.000 claims description 6
- 235000014375 Curcuma Nutrition 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 210000003491 Skin Anatomy 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 239000000284 extract Substances 0.000 abstract description 6
- 230000002124 endocrine Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory Effects 0.000 abstract description 2
- 239000000262 estrogen Substances 0.000 abstract description 2
- 241000675108 Citrus tangerina Species 0.000 abstract 3
- 241000213006 Angelica dahurica Species 0.000 abstract 2
- 244000163122 Curcuma domestica Species 0.000 abstract 2
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 2
- 240000002298 Cyperus longus Species 0.000 abstract 2
- 235000018109 Cyperus longus Nutrition 0.000 abstract 2
- 240000000628 Cyperus rotundus Species 0.000 abstract 2
- 241000935235 Fritillaria meleagris Species 0.000 abstract 2
- 235000005010 Scirpus paludosus Nutrition 0.000 abstract 2
- 240000001949 Taraxacum officinale Species 0.000 abstract 2
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract 2
- 240000004013 Trichosanthes cucumerina Species 0.000 abstract 2
- 235000003373 curcuma longa Nutrition 0.000 abstract 2
- 235000009242 dandelion Nutrition 0.000 abstract 2
- 235000014079 dandelion Nutrition 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 235000013976 turmeric Nutrition 0.000 abstract 2
- 240000003743 Bupleurum rotundifolium Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 230000036592 analgesia Effects 0.000 abstract 1
- 239000000469 ethanolic extract Substances 0.000 abstract 1
- 201000008125 pain agnosia Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 description 29
- 241000700159 Rattus Species 0.000 description 29
- 210000004369 Blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 210000004185 Liver Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 10
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 8
- 210000000481 Breast Anatomy 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 240000001624 Espostoa lanata Species 0.000 description 6
- 235000009161 Espostoa lanata Nutrition 0.000 description 6
- 206010020880 Hypertrophy Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000002445 Nipples Anatomy 0.000 description 6
- 241000282941 Rangifer tarandus Species 0.000 description 6
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 5
- 210000004291 Uterus Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000003203 everyday Effects 0.000 description 5
- 230000001575 pathological Effects 0.000 description 5
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- 210000001126 Granulation Tissue Anatomy 0.000 description 4
- 206010054107 Nodule Diseases 0.000 description 4
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000002496 gastric Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 230000001737 promoting Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 3
- 206010006232 Breast disease Diseases 0.000 description 3
- 229950002007 ESTRADIOL BENZOATE Drugs 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000003419 expectorant Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- 230000002146 bilateral Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 230000002980 postoperative Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001954 sterilising Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000002522 swelling Effects 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 229960000583 Acetic Acid Drugs 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 229940109239 Creatinine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 229960005309 Estradiol Drugs 0.000 description 1
- 206010016629 Fibroma Diseases 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 206010025482 Malaise Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000000994 depressed Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002390 hyperplastic Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002175 menstrual Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The invention discloses a Chinese medicament for treating acute and chronic mammary hyperplasia and a preparation method. The Chinese medicament consists of the following raw materials in portion by weight: 4 to 20 portions of dandelion, 2 to 10 portions of Chinese thorowax root, 2 to 10 portions of sauted green tangerine peel, 2 to 10 portions of fritillary bulb, 2 to 10 portions of turmeric root-tuber, 3 to 15 portions of snakegourd fruit, 2 to 10 portions of Chinese angelica, and 2 to 10 portions of sauted nutgrass galingale rhizome. The preparation method comprises the following steps: extracting the fritillary bulb and the Chinese angelica by using ethanol, and concentrating the ethanol extract to form an extract; extracting the dandelion, a part of green tangerine peel, the snakegourd fruit, the turmeric root-tuber and the nutgrass galingale rhizome by using water, and concentrating the water extract to form an extract; and mixing the two extracts, then evenly mixing the mixed extract and a part of green tangerine peel which is ground into fine powder, reducing the pressure and drying the mixture, crushing the mixture and adding proper amount of accessories into the mixture,evenly mixing and pelletizing the mixture, adding proper amount of dried starch and lubricant into the mixture, and evenly mixing the mixture to obtain the Chinese medicament. The Chinese medicament used for treating acute and chronic mammary hyperplasia diseases has obvious inhibition or treatment effect on the mammary hyperplasia caused by estrogen reduction and endocrine dyscrasia, and has obvious analgesia and anti-inflammatory effects at the same time.
Description
Technical field
The invention belongs to the new Chinese medicine technical field, be specifically related to a kind of Chinese medicine preparation for the treatment of the acute and chronic mammary hyperplasia disease and preparation method thereof.
Technical background
Cyclomastopathy belongs to the category of the traditional Chinese medical science " nodules of the breast ".Be young women commonly encountered diseases, frequently-occurring disease, account for more than 70% of mastopathy.Primary disease is comparatively common, and its sickness rate of domestic report and is mainly in 30～50 years old women about 10%, and the man also has generation.Modern medicine thinks that it is relevant with endocrine dysfunction, is principal character with mastalgia and lump in breast.Chinese medicine thinks that the etiology and pathogenesis of primary disease is a depression of liver-QI, the expectorant blood coagulation stasis of blood, Chong and Ren channel disorder; Wherein Chong and Ren channel disorder is for falling ill originally, and depression of liver-QI, the expectorant blood coagulation stasis of blood are the mark of morbidity, and sick position is at liver spleen kidney, and characteristic of disease is a deficiency in origin and excess in superficiality.Zhang Xiantao, Guo Sihong, Su Ying think that stagnation of QI due to depression of the liver is the main cause that nodules of the breast takes place, Xu Lvhe according to diseases such as primary disease distending pain of the breast caking, belch uncomfortable in chest in being in a very depressed state, increasing the weight of during menstrual onset, think that the primary disease pathogenesis is liver, liver influences each other depression of liver-QI, Chong and Ren channel disorder with dash appointing, through water delegation, irritability must be relaxed, Gu all diseases all subtract, so on the method for treatment based on dispersing the stagnated live-QI to relieve the stagnation of QI.Contemporary well-known doctor Gu Baihua basis clinical experience for many years proposes Chong and Ren channel disorder and the common morbific viewpoint of stagnation of QI due to depression of the liver, is extensively approved, clearly proposes " control the first treating the liver of addiction, the controlled atmosphere addiction is clear certainly " in treatment.Ni Dajun also obtains good effect with transferring liver ruling by law to treat the Chong and Ren channel disorder type mastoproliferation disease, proved the reasonability of controlling cyclomastopathy from the liver opinion, Gong Yunbin also thinks that the generation of nodules of the breast and stagnation of QI due to depression of the liver are in close relations, because of can causing blood stasis expectorant, the stagnation of QI coagulates, and the two can become paathogenic factor, and the stagnation of QI is increased the weight of.Lin Yi, Xu Guisheng think that then Chong and Ren channel disorder is the basic of nodules of the breast morbidity, and the kidney invigorating accent that adopt dash the method for appointing more in the treatment, have obtained satisfactory effect clinically.
Show the hundreds of thousands women there is every year because of suffering from this sick excision that is forced to undergo surgery according to hygiene department's statistics.Mastopathy is not distinguished by lump, if benign, adopt orally taken for curing, can eliminate at short notice fully; If virulent, even if the caking of grain of rice size is wanted untimely treatment, also can bring out canceration, the women got cyclomastopathy, mammary gland fibroma thus, and mastopathy such as lump in breast must in time be checked treatment.
Though at present clinical the chemotherapy hyperplasia of mammary glands is arranged, certain therapeutical effect is also arranged, toxic and side effects is relatively large.Though some compound Chinese medicinal preparation treatment hyperplasia of mammary glands are also arranged, and curative effect is not really desirable.For example RUKANG PIAN is a monarch drug with the Radix Astragali, is aided with 17 flavor Chinese medicines such as Concha Ostreae, Spica Prunellae, Radix Salviae Miltiorrhizae, Radix Scrophulariae, Bulbus Fritillariae Thunbergii and forms.Its production technology is that 4 kinds of compositions are pulverized, and all the other 13 kinds of flavour of a drug decoct with water secondary, and decocting liquid ethanol precipitation is removed macromolecular substances (polysaccharide etc.); Modern pharmacology studies show that the polysaccharide component in the Radix Astragali, the Bulbus Fritillariae Thunbergii has higher physiological activities, does not reach the purpose that effective ingredient is all kept.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine for the treatment of acute and chronic mammary hyperplasia, the cyclomastopathy that estrogen decrease and endocrine disturbance are caused all has obvious suppression or therapeutical effect, has tangible antiinflammatory, analgesic activity simultaneously.
Another object of the present invention is to provide a kind of preparation method for the treatment of the Chinese medicine preparation of acute and chronic mammary hyperplasia disease.
The present invention is made up of the Chinese crude drug of following parts by weight ratio: 4～20 parts of Herba Taraxacis, 2～10 parts of Radix Bupleuri, 2～10 parts of parch skins, 2～10 parts of Bulbus Fritillariae Thunbergiis, 2～10 parts of Radix Curcumaes, 3～15 parts of Fructus Trichosanthis, 2～10 parts of Radix Angelicae Sinensis, 2～10 parts of stir-fry Rhizoma Cyperis.
Best medical material ratio of weight and number of the present invention is: 12 parts of Herba Taraxacis, 6 parts of Radix Bupleuri, 6 parts of parch skins, 6 parts of Bulbus Fritillariae Thunbergiis, 6 parts of Radix Curcumaes, 9 parts of Fructus Trichosanthis, 6 parts of Radix Angelicae Sinensis, 6 parts of stir-fry Rhizoma Cyperis.
Preparation method of Chinese medicine of the present invention is made up of following steps: a, get the raw materials ready: take by weighing raw materials of traditional Chinese medicinal materials according to above-mentioned consumption, each Chinese crude drug cleaned dry, described share is standby by choosing, with Pericarpium Citri Reticulatae Viride, Rhizoma Cyperi parch, pulverize about half of Pericarpium Citri Reticulatae Viride, it is standby to cross 100 mesh sieves; B, ethanol extraction: the Radix Bupleuri of described weight quota, Bulbus Fritillariae Thunbergii, Radix Angelicae Sinensis are added the alcohol reflux twice of 6-12 times of weight, concentration 40-90%, filter then, the extractum of relative density 1.10-1.40 with filtrate recycling ethanol and when being concentrated into 60 degrees centigrade; C, water extraction: half Pericarpium Citri Reticulatae Viride, Herba Taraxaci, Radix Curcumae, Fructus Trichosanthis, Rhizoma Cyperi that pulverizing is remaining, decoct with water three times, each amount of water is 6-12 times, decocts 1-4 hour at every turn, filter the extractum of relative density 1.10-1.40 when filtrate is concentrated into 60 degrees centigrade then; D, combination drying: with two kinds of extractum of gained and Pericarpium Citri Reticulatae Viride fine powder mixing among step b and the step c, in 50-80 degree centigrade of drying under reduced pressure, pulverize the back and add the appropriate amount of auxiliary materials mixed pelletization, drying adds appropriate amount of auxiliary materials and lubricant.
The dosage form of the pharmaceutical composition finished product preparation of treatment dysmenorrhea disease of the present invention is acceptable any dosage form of routine techniques method preparation on the pharmaceutics, as granule, pill, capsule, soft capsule, tablet, mixture, oral liquid etc.
Medicine of the present invention is oral medicine, and consumption is a 10-14 gram, 3 times on the one.
Technical scheme of the present invention is based on understanding and the Therapeutic Principle of motherland's medical science to the acute and chronic mammary hyperplasia disease pathogenesis, with reference to modern pharmacological research achievement, according to depressed liver-energy dispersing and QI regulating, logical transfer to dash appoint, blood circulation promoting and blood stasis dispelling, the disappear principles of formulating prescriptions of addiction of eliminating stagnation form.By adopting Herba Taraxaci, Radix Bupleuri is monarch drug, the soothing the liver heat clearing away of tool, the disappear effect of addiction of eliminating stagnation; Fructus Trichosanthis, Bulbus Fritillariae Thunbergii, Pericarpium Citri Reticulatae Viride, Radix Curcumae are ministerial drug, and it is auxilliary then removing heat-phlegm that Herba Taraxaci, Radix Bupleuri get Fructus Trichosanthis, Bulbus Fritillariae Thunbergii, the disappear Li Youhong of addiction of eliminating stagnation; Pericarpium Citri Reticulatae Viride, Radix Curcumae are aided then dispersing the stagnated live-QI to relieve the stagnation of QI, the merit benefit of the blood stasis dispelling of circulation of qi promoting is clear; Radix Angelicae Sinensis, Rhizoma Cyperi one blood of supervising the cooking, a main circulation of qi promoting, the two blood of regulating the flow of vital energy is transferred to dash and is appointed and be adjuvant.The all medicines in full side are pulled together, long memorial liver and qi altogether, logical transfer to dash appoint blood circulation promoting and blood stasis dispelling, the disappear merit of addiction of eliminating stagnation.The present invention is on preparation technology, and the part Pericarpium Citri Reticulatae Viride is ground into fine powder, and remainder adopts different extracting method according to the not same-action of various flavour of a drug, and preparation technology's maximum possible extracts the effective ingredient of each flavour of a drug.
Show that through pharmacodynamic study gastric infusion can significantly reduce E continuously
2, P, LH content, significantly reduce the rat height of nipples and reduce the uterus coefficient, significantly reduce plasma viscosity, though whole blood viscosity and packed cell volume are had reduction trend, not statistically significant.Pathological examination shows, the Pu Chai addiction sheet that disappears can obviously reduce acinus and forms, and suppresses acinus epithelial proliferation, acinus expansion and secretions hypertrophy, and cyclomastopathy is had good inhibitory effect; The swollen granulation tissue hyperplasia of rat cotton balls there is obvious inhibitory action; The Pu Chai mice ear that addiction sheet 1,0.5g/k g group xylol causes that disappears has obvious inhibitory action; The Pu Chai mouse writhing reaction that addiction sheet 1g, 0.5g/kg Dichlorodiphenyl Acetate cause that disappears has the obvious suppression effect.
Show through toxicologic study: the Wistar rat oral gavage, in successive administration (filling stomach) 26 weeks, reversibility observed for 2 weeks.General state through observing rat administration treated animal after reaching drug withdrawal during the administration, growth promoter, diet, drinking-water, defecation etc. there is no unusual, the weight of animals and organ index and matched group be no significant difference relatively all, every detection index: routine blood test (erythrocyte, leukocyte, hemoglobin, platelet, leukocyte classification); Thrombinogen; Blood biochemical is learned and is checked relatively all no significant differences of (aspartic acid aminotransferase, ALT, alkali phosphatase, total protein, albumin, blood urea nitrogen, total gallbladder are with alcohol, blood glucose, creatinine, total bilirubin) and matched group, and the main organs specimen mirror of pathological observation and censorship rat is checked down and be there is no the pathological change relevant with drug toxicity.Show that the Pu Chai addiction sheet toxicity that disappears is lower, the clinical dosage oral administration safety is bigger.
Prove determined curative effect of the present invention through zoopery; Long term toxicity test proves that the present invention takes (3～6 months) and has no side effect substantially in therapeutic process.Adopt regulating thoroughfare and controlling vessel ruling by law to treat cyclomastopathy, not only can correct hormone disturbance, also can suppress the generation of breast carcinoma.
The specific embodiment
Embodiment 1
1, Herba Taraxaci, Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Bulbus Fritillariae Thunbergii, Radix Curcumae, Fructus Trichosanthis, Radix Angelicae Sinensis and Rhizoma Cyperi are cleaned dried, get Herba Taraxaci 400 grams, Radix Bupleuri 200 grams, Pericarpium Citri Reticulatae Viride 200 grams, Bulbus Fritillariae Thunbergii 200 grams, Radix Curcumae 200 grams, Fructus Trichosanthis 300 grams, Radix Angelicae Sinensis 200 grams, Rhizoma Cyperi 200 grams, Pericarpium Citri Reticulatae Viride, Rhizoma Cyperi parch, the 110g Pericarpium Citri Reticulatae Viride is pulverized, and it is standby to cross 100 mesh sieves;
2, ethanol extraction: Radix Bupleuri, Bulbus Fritillariae Thunbergii, Radix Angelicae Sinensis are added the alcohol reflux twice that 6-12 doubly measures 40-90%, filter then, the extractum of relative density 1.10-1.40 with filtrate recycling ethanol and when being concentrated into 60 degrees centigrade;
3, water extraction: Pericarpium Citri Reticulatae Viride, Herba Taraxaci, Fructus Trichosanthis, Radix Curcumae and Rhizoma Cyperi that pulverizing is remaining, decoct with water three times, each amount of water is 6-12 times, decocts 1-4 hour at every turn, filters the extractum of relative density 1.10-1.40 when filtrate is concentrated into 60 degrees centigrade then;
4, combination drying:,, pulverize the back and add the appropriate amount of auxiliary materials mixed pelletization in 50-80 degree centigrade of drying under reduced pressure with two kinds of extractum of gained in step 2 and the step 3 and Pericarpium Citri Reticulatae Viride fine powder mixing.
Can make tablet, capsule or electuary as required, when preparation tablet and capsule, the adjuvant of adding is generally starch, dextrin or magnesium stearate.During the preparation electuary, the adjuvant of adding is generally sugar or other sweeting agents.
Embodiment 2
Herba Taraxaci, Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Bulbus Fritillariae Thunbergii, Radix Curcumae, Fructus Trichosanthis, Radix Angelicae Sinensis and Rhizoma Cyperi cleaned dry, get Herba Taraxaci 2000 grams, Radix Bupleuri 1000 grams, Pericarpium Citri Reticulatae Viride 1000 grams, Bulbus Fritillariae Thunbergii 1000 grams, Radix Curcumae 1000 grams, Fructus Trichosanthis 1500 grams, Radix Angelicae Sinensis 1000 grams, Rhizoma Cyperi 1000 grams, Pericarpium Citri Reticulatae Viride, Rhizoma Cyperi parch, Pericarpium Citri Reticulatae Viride 550g is pulverized, and it is standby to cross 100 mesh sieves.Other step is with embodiment 1.
Embodiment 3
Herba Taraxaci, Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Bulbus Fritillariae Thunbergii, Radix Curcumae, Fructus Trichosanthis, Radix Angelicae Sinensis and Rhizoma Cyperi cleaned dry.Get 1200 parts of Herba Taraxacis, 600 parts of Radix Bupleuri, 600 parts on Pericarpium Citri Reticulatae Viride, 600 parts of Bulbus Fritillariae Thunbergiis, 600 parts of Radix Curcumaes, 900 parts of Fructus Trichosanthis, Radix Angelicae Sinensis 600 grams and Rhizoma Cyperi 600 grams, Pericarpium Citri Reticulatae Viride 310g is pulverized in Pericarpium Citri Reticulatae Viride, Rhizoma Cyperi parch, and it is standby to cross 100 mesh sieves; Other step is with embodiment 1.
Effect experiment
The medicine that the present invention makes, through zoopery, the cyclomastopathy rat had significant therapeutical effect, reduce estradiol, progesterone and lutropin content, rat hypertrophy uterus significantly dwindles, pathological examination prompting can obviously minimizing acinus forms, and suppresses acinus epithelial proliferation, acinus expansion and secretions hypertrophy, improves the ductal epithelium hyperplasia degree; The mice internal organs pain that Dichlorodiphenyl Acetate causes has significant inhibitory effect; The rat proliferative inflammation that cotton balls is caused has significant inhibitory effect; The chmice acute inflammation that xylol causes also has significant inhibitory effect; Can reduce under the pathological state plasma viscosity in the hemorheology of rat.
In zoopery, the medicine that the present invention makes is a tablet, the called after Pu bavin addiction sheet that disappears, and the medicine that contrast is tried is a RUKANG PIAN, specifically tests as follows:
Be subjected to reagent thing: the Pu Chai addiction sheet that disappears, be Film coated tablets, show sepia after removing film-coat, every gram contains crude drug 3.42 grams, and Science and Technology Ltd. provides by the Jilin great achievement, lot number: 070504; RUKANG PIAN, safe and sound Taisho Pharmaceutical company limited factory produces, lot number: 20060520.The equal gastric infusion of said medicine, matched group give same volume (20ml/kg) water.
Reagent: estradiol benzoate injection, Shanghai General Pharmaceutical Co., ltd., lot number: 050105; Progesterone injection, Zhejiang Province XianJu Pharmacy stock Co., Ltd, lot number: 070502; Dimethylbenzene, organic synthesis chemical plant, Wuhan, lot number: 891009.
Instrument: YDA-IV type blood viscometer, Beijing Hong Run reach the production of development in science and technology company limited.
Animal: Kunming mouse 20 ± 2g, be female, available from Changchun Biological Products Institute, the quality certification number: SCXK-2002-0001; Wistar rat 150～240g is female, and preclinical medicine institute of Jilin University zoopery center provides, quality certification SCXK-(Ji) 2003-0001.
Each experiment body weight difference mice is no more than 4g, and rat is no more than 30g.
Method and result
One, to the influence of hyperplasia of mammary gland model rat
Get 60 of healthy adult unpregnancy female rats, divide equally six groups at random, be respectively matched group, model group, positive control RUKANG PIAN group (0.28g/kg) and Pu bavin disappear addiction sheet group (0.7,0.35,0.175g/kg).Except that matched group, all the other each groups after 25 days, change intramuscular injection every day Progesterone 0.5mg/kg into, continuous 5 days by 0.5mg/kg intramuscular injection every day estradiol benzoate.Each group is irritated stomach and is subjected to the reagent thing, 4 weeks of successive administration simultaneously.After the last administration 24 hours, with the anesthesia of 20% urethane, abdominal aortic blood 5ml, after the 2ml natural subsidence, centrifugal (3000r/min) 5min gets upper serum and is used to measure hormone-content, the sodium citrate anticoagulant of 3ml blood, be used to measure hemorheology index, rat is put to death in the cervical vertebra dislocation then, with second pair of height of nipples of vernier caliper measurement, draw materials through basad maximum tangent plane of nipple again, conventional fixing, paraffin Bao Li, section, HE dyeing, light microscopic is observed histopathology down and is changed.Separating uterus is rejected fatty tissue on every side again, weighs rapidly.The results are shown in Table 1, table 2, table 3.
The influence of addiction sheet that disappear of table 1. Pu bavin to hyperplasia of mammary gland model rat uterus coefficient and height of nipples
Compare * P＜0.05, * * P＜0.01.x ± S. with model group
The influence of addiction sheet that disappear of table 2. Pu bavin to hyperplasia of mammary gland model rat hormonal readiness
Compare * P＜0.05, * * P＜0.01.x ± S. with model group
The influence of addiction sheet that disappear of table 3. Pu bavin to hemorheology of rat
Compare * P＜0.05, * * P＜0.01 with model group
The result shows that rat muscle injection estradiol benzoate and Progesterone cause rat mammary gland hypertrophy, E
2, normal matched group obviously raises for P, LH content, perusal as seen, the rat nipple is red and swollen or increase, and shows that the rat mammary gland model of hyperplasia sets up; Disappear addiction sheet 0.7,0.35g/kg group and RUKANG PIAN 028g/kg group of Pu Chai all can significantly reduce E
2, P, LH content; Significantly reduce the rat height of nipples and reduce the uterus coefficient; Pu Chai addiction sheet 0.7, the 0.35g/kg group that disappears significantly reduces plasma viscosity, though whole blood viscosity and packed cell volume are had reduction trend, not statistically significant.
Pathological examination shows, the mammary gland of control rats all finds no the cyclomastopathy symptom, the obvious hypertrophy of the lobules of mammary gland of model group rat, conduit cavity and acinus expansion are obviously, acinus increases, and lumen of gland and ductal ectasia also have secretions, and disappear addiction sheet high dose group and RUKANG PIAN group of Pu Chai can obviously reduce acinus and form, suppress acinus epithelial proliferation, acinus expansion and secretions hypertrophy, to cyclomastopathy in, low dose group is more effective.
Two, to the bullate influence of rat granuloma
Get 50 of rats, be divided into five groups at random, be respectively matched group, positive control RUKANG PIAN group (0.28g/kg) and the Pu bavin addiction sheet group (0.7,0.35,0.175g/kg) that disappears.The etherization rat, cut off the 1cm osculum respectively after the sterilization of bilateral axillary fossa, each implantation-50mg sterilization cotton balls (autoclaving of bilateral, each adds ampicillin 10mg/ml, 50 ℃ of oven for drying), each organizes preceding 3 days of rat Rhizoma Atractylodis Macrocephalae to postoperative administration every day in 7 day 1 time, amount to 10 times, 1 hour (postoperative 7 days) sacrificed by decapitation rat is cut former otch after the last administration, and cotton balls and hyperplastic tissue are together taken out, 70 ℃ of dryings, accurately weigh, claim to such an extent that weight deducts cotton balls weight and is the granulation tissue hyperplasia degree, the results are shown in Table 2.
The influence of addiction sheet that disappear of table 4. Pu bavin to the rat chronic granulation tissue hyperplasia
With matched group relatively: * * P＜0.01*P＜0.05.x ± S.
The result shows, disappear addiction sheet 0.7,0.35,0.175g/kg and RUKANG PIAN 0.28g/kg of Pu Chai has obvious inhibitory action to the swollen granulation tissue hyperplasia of rat cotton balls, and the Pu Chai addiction sheet 0.7g/kg group effect that disappears is the strongest.
Three, xylol causes the influence of mice ear
Get 50 of 20g ± 2g mice, be divided into 5 groups at random, be respectively matched group (distilled water), positive control drug RUKANG PIAN group (0.4g/kg) and the Pu bavin addiction sheet group (1,0.5,0.25g/kg) that disappears.The gastric infusion of dosage shown in pressing, every day 1 time, continuous 8 days, matched group gave the equal-volume distilled water.Smeared dimethylbenzene 0.1ml/ only in the Mus auris dextra in 1 hour after the last administration, be coated with back 4h and put to death mice, along the auricle baseline with directly through being that the sharp card punch of 9mm is laid the ears sheet in same area, weigh respectively, calculate its difference as the swelling degree.The results are shown in Table 5.
The disappear influence of the mice auricle swelling degree that addiction sheet xylol causes of table 5 Pu bavin
Compare * P＜0.05 with matched group
The result shows: disappear addiction sheet 1,0.5g/kg of RUKANG PIAN 0.4g/kg group and Pu bavin organized the mice ear that xylol causes and had obvious inhibitory action, relatively has significant difference with matched group.
Four, Dichlorodiphenyl Acetate causes the influence of mouse writhing reaction
Get 50 of mices, divide equally five groups at random, be respectively matched group (distilled water), positive control drug RUKANG PIAN group (0.4g/kg) and the Pu bavin addiction sheet group (1,0.5,0.25g/kg) that disappears.Hungry 15h before the administration group mice gastric infusion every day one-time continuous administration 8 days, last administration, 1h respectively organizes mouse peritoneal and only injects 0.8% glacial acetic acid 0.2ml/ after the last administration, and mouse writhing number of times in back 5 minutes～15 minutes injected in record, the results are shown in Table 6.
The table 6. Pu bavin addiction sheet Dichlorodiphenyl Acetate that disappears causes the influence of mice pain reaction
Compare * P＜0.05 with matched group
The result shows, RUKANG PIAN 0.4g/kg and the Pu Chai mouse writhing reaction that addiction sheet 1,0.5g/kg Dichlorodiphenyl Acetate cause that disappears has the obvious suppression effect.
Claims (3)
1, a kind of Chinese medicine for the treatment of acute and chronic mammary hyperplasia, it is characterized in that: form 4～20 parts of Herba Taraxacis, 2～10 parts of Radix Bupleuri, 2～10 parts of parch skins, 2～10 parts of Bulbus Fritillariae Thunbergiis, 2～10 parts of Radix Curcumaes, 3～15 parts of Fructus Trichosanthis, 2～10 parts of Radix Angelicae Sinensis, 2～10 parts of stir-fry Rhizoma Cyperis by following parts by weight of traditional Chinese medicines material.
2, the Chinese medicine of treatment acute and chronic mammary hyperplasia according to claim 1, it is characterized in that: form 12 parts of Herba Taraxacis, 6 parts of Radix Bupleuri, 6 parts of parch skins, 6 parts of Bulbus Fritillariae Thunbergiis, 6 parts of Radix Curcumaes, 9 parts of Fructus Trichosanthis, 6 parts of Radix Angelicae Sinensis, 6 parts of stir-fry Rhizoma Cyperis by following parts by weight of traditional Chinese medicines material.
3, the preparation method of Chinese medicine of the described treatment acute and chronic mammary hyperplasia of a kind of claim 1 is characterized in that may further comprise the steps:
A, get the raw materials ready: get 4～20 parts of Herba Taraxacis, 2～10 parts of Radix Bupleuri, 2～10 parts of parch skins, 2～10 parts of Bulbus Fritillariae Thunbergiis, 2～10 parts of Radix Curcumaes, 3～15 parts of Fructus Trichosanthis, 2～10 parts of Radix Angelicae Sinensis by weight, fry 2～10 parts of Rhizoma Cyperis, after aforementioned various medical material is cleaned and is dried, with Pericarpium Citri Reticulatae Viride, Rhizoma Cyperi parch, pulverize about half of Pericarpium Citri Reticulatae Viride, it is standby to cross 100 mesh sieves;
B, ethanol extraction: Radix Bupleuri, Bulbus Fritillariae Thunbergii, Radix Angelicae Sinensis are added the alcohol reflux twice of 6-10 times of weight, concentration 40-90%, filter then, the extractum of relative density 1.10-1.40 with filtrate recycling ethanol and when being concentrated into 60 degrees centigrade;
C, water extraction: half Pericarpium Citri Reticulatae Viride, Herba Taraxaci, Fructus Trichosanthis, Radix Curcumae, Rhizoma Cyperi that pulverizing is remaining, decoct with water three times, the 6-12 that each amount of water is a raw material weight doubly decocted 1-4 hour at every turn, filter the extractum of relative density 1.10-1.40 when filtrate is concentrated into 60 degrees centigrade then;
D, combination drying: with two kinds of extractum of gained and Pericarpium Citri Reticulatae Viride fine powder mixing among step b and the step c, in 50-80 degree centigrade of drying under reduced pressure, pulverize the back and add the appropriate amount of auxiliary materials mixed pelletization, add proper amount of dry starch and lubricant, mixing gets Chinese medicine of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810051138 CN101664533B (en) | 2008-09-04 | 2008-09-04 | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810051138 CN101664533B (en) | 2008-09-04 | 2008-09-04 | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101664533A true CN101664533A (en) | 2010-03-10 |
| CN101664533B CN101664533B (en) | 2013-04-03 |
Family
ID=41801415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810051138 Active CN101664533B (en) | 2008-09-04 | 2008-09-04 | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101664533B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908603A (en) * | 2012-10-30 | 2013-02-06 | 王凤 | Chinese medicament for treating hyperplasia of mammary glands |
| CN107007772A (en) * | 2017-05-15 | 2017-08-04 | 铜仁市凯盛水产养殖有限公司 | A kind of cold water fish forage Chinese medicine additive and preparation method thereof |
| CN107569651A (en) * | 2017-09-13 | 2018-01-12 | 李晓艳 | A kind of emplastrum for treating proliferation of mammary gland mastitis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100490885C (en) * | 2006-03-21 | 2009-05-27 | 吉林省中医中药研究院 | Medicine for treating hyperplasia of mammary glands and its preparing method |
-
2008
- 2008-09-04 CN CN 200810051138 patent/CN101664533B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908603A (en) * | 2012-10-30 | 2013-02-06 | 王凤 | Chinese medicament for treating hyperplasia of mammary glands |
| CN102908603B (en) * | 2012-10-30 | 2014-06-18 | 王凤 | Chinese medicament for treating hyperplasia of mammary glands |
| CN107007772A (en) * | 2017-05-15 | 2017-08-04 | 铜仁市凯盛水产养殖有限公司 | A kind of cold water fish forage Chinese medicine additive and preparation method thereof |
| CN107569651A (en) * | 2017-09-13 | 2018-01-12 | 李晓艳 | A kind of emplastrum for treating proliferation of mammary gland mastitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101664533B (en) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104162094B (en) | A kind of Chinese medicine composition and its pharmaceutical preparation for treating Obesity-type Polycystic Ovary Syndrome | |
| WO2009062338A1 (en) | A lactogenic chinese medicine for treatment and prevention of gynecopathy, methods of preparation and uses thereof | |
| CN101664533B (en) | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method | |
| CN102526342B (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| CN104491802A (en) | Application of traditional Chinese medicine preparation in preparation of medicine for treating acute or chronic gastritis | |
| CN106362104A (en) | Pharmaceutical composition for treating polycystic ovary syndrome in adolescence | |
| CN106334060A (en) | Pharmaceutical composition for treating endomorphy type polycystic ovarian syndrome | |
| CN101664541B (en) | Medicament for treating dysmenorrhoea and preparation method thereof | |
| CN104436121B (en) | It is a kind of to treat irregular menstruation, small distention and fullness in the abdomen, the medicine to fail to be impregnated for a long time | |
| CN106390035A (en) | Traditional Chinese medicine preparation for treating mammary gland hyperplasia | |
| CN101564483B (en) | Liver smoothing for treating hyperplasia of mammary glands | |
| CN113599475B (en) | Middle-warming and kidney-tonifying composition for treating polycystic ovarian syndrome and preparation method and application thereof | |
| CN103212030A (en) | Traditional Chinese medicine for treating liver depression type hyperplasia of mammary glands and preparation method thereof | |
| CN102406811A (en) | Traditional Chinese medicine composition for treating ovarian cyst | |
| CN102008688B (en) | Medicament for treating periodic psychosis | |
| CN106540168B (en) | Traditional Chinese medicine composition for treating kidney deficiency type irregular menstruation, amenorrhea and infertility as well as preparation method and application thereof | |
| CN101259241A (en) | Chinese medicinal composition for treating endometriosis symptoms and preparation thereof | |
| CN104173857A (en) | Traditional Chinese medicine for treating yin-yang-deficiency diabetes mellitus II and preparation method of traditional Chinese medicine | |
| CN104147268A (en) | Traditional Chinese medicine composition and preparation thereof for treating hepatic and gallbladder calculus | |
| CN103920100A (en) | Medicine composition for treating mammary gland hyperplasia | |
| CN102309683B (en) | Application of traditional Chinese medicinal composition in preparing medicines for treating hysteromyoma | |
| CN103463365A (en) | Medicament for treating ewe habitual abortion | |
| CN101670067A (en) | Medicament for treating endometriosis and preparation process thereof | |
| CN102038771B (en) | Application of discolor cinquefoil herb in preparation of medicines for treating hysteromyoma | |
| CN100534519C (en) | Medicine for treating functional metrorrhagia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JILIN MODERN CHINESE MEDICINE ENGINEERING RESEARCH Free format text: FORMER OWNER: LI YANHUA Effective date: 20131010 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20131010 Address after: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin, China Patentee after: Jilin Modern Chinese Medicine Engineering Research Center Co., Ltd. Address before: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin, China Patentee before: Li Yanhua |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20181119 Address after: No. 39, Modified Road, Tonghua City, Jilin Province, 134000 Patentee after: Tongyao Pharmaceutical Group Corporation Address before: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin, China Patentee before: Jilin Modern Chinese Medicine Engineering Research Center Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A traditional Chinese medicine for treating acute and chronic hyperplasia of mammary glands and its preparation method Effective date of registration: 20201126 Granted publication date: 20130403 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: Tongyao Pharmaceutical Group Corp. Registration number: Y2020220000086 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211221 Granted publication date: 20130403 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: Tongyao Pharmaceutical Group Corp. Registration number: Y2020220000086 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |